SCHEMBL7416446

SCHEMBL7416446

CCOc1ccccc1C(C(=O)O)S(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 2/20 0.40
PTPRC P08575 1/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 2/20 0.40
HCRTR1 O43613 1/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NOD2 Q9HC29 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7417569 0.79 MEN1 (0.43) GLAL3MBTL1ATMCTDSP1ALDH1A1
SCHEMBL28158526 0.74 L3MBTL1 (0.56) GLAL3MBTL1CTDSP1ALDH1A1HPGD
SCHEMBL4022075 0.73 SRC (0.42) ATMALDH1A1TDP1KMT2AMEN1
SCHEMBL28222557 0.73 L3MBTL1 (0.54) GLAL3MBTL1CTDSP1ALDH1A1HPGD
SCHEMBL6774272 0.71 PDE4A (0.53) ALDH1A1MAPTTDP1NPC1GAA
SCHEMBL9424144 0.71 L3MBTL1 (0.61) GLAL3MBTL1ALDH1A1HPGDMAPT
SCHEMBL28297533 0.70 SRC (0.55) L3MBTL1KMT2APOLBNPSR1
SCHEMBL11092157 0.70 SRC (0.64) ALDH1A1LMNACYP2C19
SCHEMBL21850061 0.70 L3MBTL1 (0.50) GLAL3MBTL1CTDSP1ALDH1A1HPGD
SCHEMBL11603748 0.69 ALDH1A1 (0.54) GLAL3MBTL1ATMCTDSP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163214-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 Merck Frosst Canada & Co. (CA) 2001-12-19 EP disclosed
US-6225288-B1 IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING MERK FROSST CANADA & CO. (CA) 2001-05-01 US disclosed
WO-2000055127-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 MERCK FROSST CANADA & CO. (CA) 2000-09-21 WO disclosed